Sherlock Biosciences is a molecular diagnostics company founded in 2019 out of the Broad Institute to commercialize SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), the CRISPR-based nucleic-acid detection method developed in the Zhang lab, alongside INSPECTR, an ambient-temperature synthetic-biology amplification platform. In May 2020 it received the first FDA Emergency Use Authorization ever granted to a CRISPR-based diagnostic, for SARS-CoV-2. The company developed disposable, instrument-free molecular self-tests, led by a combined Chlamydia trachomatis and Neisseria gonorrhoeae assay. OraSure Technologies acquired Sherlock Biosciences in December 2024 and absorbed it into its rapid-diagnostics portfolio; the sherlock.bio domain now permanently redirects to orasure.com. Sherlock Biosciences is a laboratory diagnostics developer and has never operated a public developer program, HTTP API, or machine-readable API contract.
Sherlock Biosciences is profiled on the APIs.io network. Tagged areas include Diagnostics, Molecular Diagnostics, CRISPR, Biotechnology, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: sherlock-biosciences
name: Sherlock Biosciences
description: Sherlock Biosciences is a molecular diagnostics company founded in 2019 out of the Broad Institute to commercialize
SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), the CRISPR-based nucleic-acid detection method developed
in the Zhang lab, alongside INSPECTR, an ambient-temperature synthetic-biology amplification platform. In May 2020 it received
the first FDA Emergency Use Authorization ever granted to a CRISPR-based diagnostic, for SARS-CoV-2. The company developed
disposable, instrument-free molecular self-tests, led by a combined Chlamydia trachomatis and Neisseria gonorrhoeae assay.
OraSure Technologies acquired Sherlock Biosciences in December 2024 and absorbed it into its rapid-diagnostics portfolio;
the sherlock.bio domain now permanently redirects to orasure.com. Sherlock Biosciences is a laboratory diagnostics developer
and has never operated a public developer program, HTTP API, or machine-readable API contract.
url: https://raw.githubusercontent.com/api-evangelist/sherlock-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
deliveryModel:
model: library
open_source: false
commercial: false
callable_host: false
label: Library · distributed through package registries, no callable service
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
- url: https://sherlock.bio/
status: 301
note: declared website redirects to https://orasure.com/ — a different registrable domain (sherlock.bio -> orasure.com),
possible rename or acquisition (probed 2026-09-03, roadmap#169)
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-27'
modified: '2026-08-27'
tags:
- Diagnostics
- Molecular Diagnostics
- CRISPR
- Biotechnology
- Life Sciences
- Healthcare
- Infectious Disease
- Point of Care Testing
- Synthetic Biology
- Bioinformatics
- Acquired
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/sherlock-biosciences-domain-security.yml
- type: Website
url: https://sherlock.bio/
- type: ParentCompany
url: https://orasure.com/
- type: GitHubOrganization
url: https://github.com/SherlockBiosciences
- type: Packages
url: packages/sherlock-biosciences-packages.yml
- type: LLMsTxt
url: llms/sherlock-biosciences-llms.txt
x-enrichment:
date: '2026-08-27'
status: minimal
artifacts_added: 4
pass: local-v1
x-coverage:
state: none
reason: defunct
detail: Sherlock Biosciences was acquired by OraSure Technologies in December 2024 and fully absorbed; its own domain sherlock.bio
now returns a bare 301 to orasure.com, and every contract-discovery and .well-known path probed on sherlock.bio, orasure.com
and www.orasure.com returned 404, leaving a molecular-diagnostics company that never ran a developer program with no surviving
API surface of any kind.
evidence:
- url: https://sherlock.bio/
status: 301
- url: https://sherlock.bio/openapi.json
status: 404
- url: https://sherlock.bio/.well-known/agent-card.json
status: 404
- url: https://orasure.com/openapi.json
status: 404
- url: https://www.orasure.com/.well-known/api-catalog
status: 404
- url: https://github.com/SherlockBiosciences
status: 200
checked: '2026-08-27'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.